Cytisine + Video Messaging for Smoking Cessation
(PREVENT Trial)
Trial Summary
What is the purpose of this trial?
PREVENT is a multicentre, 2x2 factorial, randomized clinical trial that aims to determine the effect of cytisine versus placebo, as well as the effect of video messaging to support smoking cessation versus standard of care in perioperative patients. This trial aims to investigate the effects of cytisine and text messaging on 6-month continuous abstinence rates. PREVENT will also assess secondary outcomes at 30 days, 56 days and 6 months post-randomization: 7-day point prevalence abstinence, urge to smoke, time to first lapse, time to relapse, number of cigarettes smoking if still smoking, pulmonary complications, vascular complications, wound and infectious complications, stroke, time in hospital and acute hospital care.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does mention that you cannot be using any smoking cessation treatment when you join the study.
What data supports the effectiveness of the treatment Cytisine + Video Messaging for Smoking Cessation?
Research shows that digital and mobile messaging interventions, like text and video messaging, can help people quit smoking by providing real-time support and motivation. Additionally, similar interventions have been found feasible and acceptable, with some studies showing increased quit rates when combined with other therapies.12345
Is the combination of Cytisine and video messaging safe for smoking cessation?
Cytisine has been used for over 40 years in Central and Eastern Europe for smoking cessation and is generally considered safe, with studies showing it is effective and well-tolerated. However, more detailed studies on its safety profile are needed, and there is no specific safety data available for its use with video messaging.678910
How does the drug cytisine differ from other smoking cessation treatments?
Cytisine is unique because it is a low-cost, plant-based drug that acts as a partial agonist on nicotine receptors, helping to reduce nicotine withdrawal symptoms and cravings. Unlike other treatments like nicotine replacement therapy, cytisine has been used for decades in Eastern Europe and offers a natural alternative with a different mechanism of action.7891011
Research Team
Sandra Ofori, Dr.
Principal Investigator
Population Health Research Institute
Flavia Kessler Borges, Dr.
Principal Investigator
Population Health Research Institute
Eligibility Criteria
The PREVENT trial is for adults over 18 who smoke at least 10 cigarettes daily, haven't quit for more than 6 months in the past year, and are scheduled for surgery within the next 1-28 days. Participants must not be on smoking cessation treatments but should have a smartphone with an active data plan.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cytisine or placebo and video messaging or standard care for smoking cessation
Follow-up
Participants are monitored for smoking cessation outcomes and complications
Treatment Details
Interventions
- Cytisine
- Text Messaging
- Video Messaging
Find a Clinic Near You
Who Is Running the Clinical Trial?
Population Health Research Institute
Lead Sponsor